Every one of those 1 sits in a single category, pharma. Aurobindo Pharma USA, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Aurobindo Pharma Ltd. appears in 1 tracked Biotech story from July 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Aurobindo Pharma Ltd.
Every one of those 1 sits in a single category, pharma. Aurobindo Pharma USA, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Aurobindo Pharma Ltd. appears in 1 tracked Biotech story from July 27, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Aurobindo Pharma Ltd.. Shared-story counts are live from our verified record — not editorial picks.
The U.S. Federal Trade Commission approved Aurobindo Pharma USA’s $250 million acquisition of Lannett Company LLC, clearing the final regulatory hurdle.
Aurobindo Pharma’s US subsidiary receives FTC clearance for its $250 million cash-free acquisition of Lannett, adding a complex generics and controlled substances portfolio expected to be immediately accretive to EPS and generate significant synergies.